Bank of New York Mellon Corp bought a new position in shares of GeneDx Holdings Corp. (NASDAQ:WGS – Free Report) during the second quarter, Holdings Channel.com reports. The fund bought 37,918 shares of the company’s stock, valued at approximately $991,000.
Several other institutional investors and hedge funds have also made changes to their positions in WGS. Calamos Advisors LLC purchased a new stake in GeneDx in the 2nd quarter valued at $1,137,000. Assenagon Asset Management S.A. purchased a new stake in shares of GeneDx in the second quarter valued at about $9,575,000. Legal Advantage Investments Inc. acquired a new stake in shares of GeneDx during the second quarter worth about $518,000. Oracle Investment Management Inc. grew its holdings in shares of GeneDx by 531.7% during the first quarter. Oracle Investment Management Inc. now owns 1,126,607 shares of the company’s stock worth $10,286,000 after buying an additional 948,253 shares during the last quarter. Finally, Gagnon Securities LLC increased its position in GeneDx by 59.3% in the 1st quarter. Gagnon Securities LLC now owns 556,305 shares of the company’s stock valued at $5,079,000 after acquiring an additional 207,027 shares during the period. 61.72% of the stock is owned by hedge funds and other institutional investors.
Insider Transactions at GeneDx
In other GeneDx news, CEO Katherine Stueland sold 2,154 shares of the company’s stock in a transaction on Monday, July 29th. The stock was sold at an average price of $33.54, for a total value of $72,245.16. Following the sale, the chief executive officer now owns 92,550 shares of the company’s stock, valued at $3,104,127. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, major shareholder Opko Health, Inc. sold 50,000 shares of GeneDx stock in a transaction that occurred on Monday, July 1st. The stock was sold at an average price of $26.63, for a total transaction of $1,331,500.00. Following the completion of the transaction, the insider now directly owns 3,508,603 shares in the company, valued at approximately $93,434,097.89. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Katherine Stueland sold 2,154 shares of the company’s stock in a transaction that occurred on Monday, July 29th. The shares were sold at an average price of $33.54, for a total value of $72,245.16. Following the completion of the sale, the chief executive officer now directly owns 92,550 shares in the company, valued at approximately $3,104,127. The disclosure for this sale can be found here. Insiders have sold 743,868 shares of company stock valued at $24,114,996 in the last quarter. 28.10% of the stock is currently owned by corporate insiders.
Analyst Upgrades and Downgrades
View Our Latest Research Report on GeneDx
GeneDx Price Performance
GeneDx stock opened at $40.40 on Friday. The company has a debt-to-equity ratio of 0.27, a quick ratio of 2.22 and a current ratio of 2.38. GeneDx Holdings Corp. has a one year low of $1.16 and a one year high of $43.32. The company has a market cap of $1.06 billion, a P/E ratio of -7.80 and a beta of 2.29. The business has a fifty day moving average of $33.64 and a two-hundred day moving average of $23.59.
GeneDx (NASDAQ:WGS – Get Free Report) last released its quarterly earnings data on Tuesday, July 30th. The company reported ($0.11) EPS for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.15. GeneDx had a negative net margin of 48.21% and a negative return on equity of 22.71%. The firm had revenue of $70.51 million for the quarter, compared to the consensus estimate of $58.90 million. As a group, analysts predict that GeneDx Holdings Corp. will post -0.75 earnings per share for the current fiscal year.
GeneDx Profile
GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.
Featured Stories
- Five stocks we like better than GeneDx
- What Investors Need to Know to Beat the Market
- Take Advantage of Village Farms Stock as Cannabis Market Evolves
- How to Use Stock Screeners to Find Stocks
- MarketBeat Week in Review – 9/16 – 9/20
- What Are Some of the Best Large-Cap Stocks to Buy?
- Don’t Miss These 3 Retail Stocks for Fall Gains
Want to see what other hedge funds are holding WGS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GeneDx Holdings Corp. (NASDAQ:WGS – Free Report).
Receive News & Ratings for GeneDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GeneDx and related companies with MarketBeat.com's FREE daily email newsletter.